GPhA Resorts To Citizen Petition On Biosimilar Naming
This article was originally published in The Pink Sheet Daily
Executive Summary
Trade group argues that if unique names will be required for biosimilars then they also should be required of innovator products following a manufacturing change that is approved based on comparability testing.